BRPI0909745A2 - novos usos de 4-fenil butirato de sódio (4pba) e de seus sais farmaceuticamente aceitáveis - Google Patents

novos usos de 4-fenil butirato de sódio (4pba) e de seus sais farmaceuticamente aceitáveis

Info

Publication number
BRPI0909745A2
BRPI0909745A2 BRPI0909745A BRPI0909745A BRPI0909745A2 BR PI0909745 A2 BRPI0909745 A2 BR PI0909745A2 BR PI0909745 A BRPI0909745 A BR PI0909745A BR PI0909745 A BRPI0909745 A BR PI0909745A BR PI0909745 A2 BRPI0909745 A2 BR PI0909745A2
Authority
BR
Brazil
Prior art keywords
4pba
sodium
pharmaceutically acceptable
acceptable salts
novel uses
Prior art date
Application number
BRPI0909745A
Other languages
English (en)
Portuguese (pt)
Inventor
Lourdes Ricobaraza Abarquero Ana
Maria Garcia Osta Ana
Sara Frechilla Manso Diana
Alberto Péres Mediavilla Luis
Original Assignee
Proyecto De Biomedicina Cima S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima S L filed Critical Proyecto De Biomedicina Cima S L
Publication of BRPI0909745A2 publication Critical patent/BRPI0909745A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0909745A 2008-03-13 2009-03-06 novos usos de 4-fenil butirato de sódio (4pba) e de seus sais farmaceuticamente aceitáveis BRPI0909745A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200800736A ES2332687B1 (es) 2008-03-13 2008-03-13 Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
PCT/ES2009/000121 WO2009112609A1 (es) 2008-03-13 2009-03-06 Nuevos usos del 4-fenilbutirato de sodio (4 pba) y sus sales farmacéuticamente aceptables

Publications (1)

Publication Number Publication Date
BRPI0909745A2 true BRPI0909745A2 (pt) 2019-09-24

Family

ID=40691368

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909745A BRPI0909745A2 (pt) 2008-03-13 2009-03-06 novos usos de 4-fenil butirato de sódio (4pba) e de seus sais farmaceuticamente aceitáveis

Country Status (11)

Country Link
US (1) US20110027251A1 (enExample)
EP (1) EP2272515A1 (enExample)
JP (1) JP2011518119A (enExample)
CN (1) CN102036665A (enExample)
AU (1) AU2009224613A1 (enExample)
BR (1) BRPI0909745A2 (enExample)
CA (1) CA2718463A1 (enExample)
ES (1) ES2332687B1 (enExample)
MX (1) MX2010009933A (enExample)
RU (1) RU2010138638A (enExample)
WO (1) WO2009112609A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080827A1 (es) * 2010-04-06 2012-05-09 Bayer Cropscience Ag Utilizacion del acido 4- fenil- butirico y/o de sus sales para el aumento de la tolerancia al estres en plantas
CN101973868B (zh) * 2010-11-12 2012-08-15 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅰ型结晶及其制备方法
EP2599479A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment of alzheimer's disease
WO2013149091A1 (en) 2012-03-29 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Composition and method for treating neurodegenerative disease
CN102757334B (zh) * 2012-07-30 2014-05-28 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅱ型晶体及其制备方法
US9872865B2 (en) * 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
EP3019865A4 (en) * 2013-07-12 2017-04-05 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
US11224668B2 (en) * 2016-02-29 2022-01-18 Neurovation Labs, Inc. Compositions and methods to detect GluA1 in brain and to identify the presence of GluA1-mediated PTSD
IL296490B1 (en) 2016-03-15 2025-09-01 Acer Therapeutics Inc Tasty compositions containing sodium phenylbutyrate and their uses
JP6962572B2 (ja) * 2016-03-18 2021-11-05 学校法人同志社 ２，４−ジアミノフェノール誘導体、及び、タウ及び／又はアミロイドβの凝集阻害剤
JP2019214546A (ja) * 2018-06-11 2019-12-19 学校法人福岡大学 終末糖化産物生成抑制剤及び医薬組成物
JP2020083827A (ja) * 2018-11-27 2020-06-04 国立研究開発法人農業・食品産業技術総合研究機構 ケミカルシャペロンまたは神経細胞死の抑制剤
WO2020139874A1 (en) * 2018-12-27 2020-07-02 Virginia Polytechnic Institute And State University Chemically programmed neutrophils and uses thereof
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US20240108593A1 (en) * 2020-12-07 2024-04-04 University Of Miami Method of treating polyamine imbalance-related disorders
JP2024543053A (ja) * 2021-11-08 2024-11-19 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
CN116099003A (zh) * 2022-11-28 2023-05-12 核工业总医院 内质网应激抑制剂在放射性认知功能障碍药物中的应用
WO2024165757A1 (en) 2023-02-10 2024-08-15 Ludwig-Maximilians-Universität München Oral phenylbutyrate for treatment of human 4-repeat tauopathies
CN117338763A (zh) * 2023-11-01 2024-01-05 重庆医科大学 丁酸钠在制备治疗帕金森病的药物中的应用及其治疗新靶标

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
DE69706566T2 (de) * 1996-08-13 2002-07-11 P.N. Gerolymatos S.A., Kruoneri Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2002090534A1 (en) * 2001-05-02 2002-11-14 The Regents Of The University Of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate

Also Published As

Publication number Publication date
JP2011518119A (ja) 2011-06-23
US20110027251A1 (en) 2011-02-03
CN102036665A (zh) 2011-04-27
WO2009112609A1 (es) 2009-09-17
CA2718463A1 (en) 2009-09-17
ES2332687A1 (es) 2010-02-10
MX2010009933A (es) 2010-12-06
RU2010138638A (ru) 2012-04-20
ES2332687B1 (es) 2011-01-10
EP2272515A1 (en) 2011-01-12
AU2009224613A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
BRPI0909745A2 (pt) novos usos de 4-fenil butirato de sódio (4pba) e de seus sais farmaceuticamente aceitáveis
PT2473528E (pt) Formulações estáveis de polipéptidos e seus usos
PT2643322T (pt) Sais e formas cristalinas de um agente indutor de apoptose
BRPI0918513A2 (pt) formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu uso
HRP20190100T1 (hr) Oralne formulacije analoga citidina i postupci za njihovu upotrebu
BRPI0909185A2 (pt) Derivado de vitamina e e seus usos
NO2017033I2 (no) baricitinib og farmasøytisk akseptable salter derav
BRPI0908175A2 (pt) derivados de polimixina e composição farmacêuticas contendo os derivados de polimixina seus usos e métodos de preparação
BRPI1008045A2 (pt) derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BR112012000660A2 (pt) compostos heterociclos e seus usos
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
DK3719018T3 (da) Purin og deazapurinderivater som farmaceutiske forbindelser
BR112012001061A2 (pt) glicosídeos 2,3-fluorados como inibidores de neuraminidase e seu uso como antivirais
BR112012002553A2 (pt) formulações terapêuticas de protetor solar com vitamina d e métodos para seus usos
BR112012001915A2 (pt) derivado de análogo de glp-1 ou seus sais farmacêuticos e seu uso.
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
NL301214I2 (nl) Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI0908225A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0920183A2 (pt) derivados de fenetilamida e seus analogos heterociclicos
BRPI0919322A2 (pt) derivados de glicosideo e usos dos mesmos como inibidores sglt
BRPI0920209A2 (pt) conjugados de agonistas de glp-1 e usos dos mesmos
BRPI0817234A2 (pt) Análogos de azacitidina e seus usos
BRPI1010239A2 (pt) endoglucanases aprimoradas, derivados e seus usos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.